ArticleLipids2026
Lipid Profile in Primary Aldosteronism: Cross-Sectional and Post-Treatment Analyses.
Article in Lipids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between primary aldosteronism (PA) and lipid metabolism remains controversial, with inconsistent findings reported in the literature. This study aimed to clarify PA's impact on the lipid profile using both a cross-sectional comparison with essential hypertension (EH) controls and a longitudinal within-patient pre-post treatment analysis in a North African tertiary-center cohort. This retrospective study included 112 patients with PA and 115 contemporaneously hospitalized patients with EH in whom secondary hypertension had been excluded. Sociodemographic, clinical, and biochemical variables (fasting blood glucose, HbA1c, lipid profile, creatinine, potassium, baseline aldosterone levels, and aldosterone-to-renin ratio), as well as therapeutic data, were collected at admission in both groups. In the PA group, clinical and biological parameters performed 1 year after specific PA management were recorded. Triglyceride levels were significantly higher in patients with PA not receiving lipid-lowering therapy (1.47 (1.13-1.92) vs. 1.24 (1.02-1.69) mmol/L; p = 0.04) but this difference disappeared after multivariable adjustment for age, sex, BMI, and fasting glucose. A baseline aldosterone level > 200 pg/mL was associated with lower triglyceride levels (1.35 (1.02-1.81) vs. 1.81 (1.35-2.15) mmol/L; p = 0.01). Patients with PA who underwent adrenalectomy demonstrated a significant increase in triglyceride levels at 1 year (1.52 (1.32-2.11) vs. 2.08 (1.38-2.50) mmol/L; p = 0.04). The estimated glomerular filtration rate declined significantly 1 year after PA specific treatment (84.9 ± 19.7 vs. 73.6 ± 24.9 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.